Literature DB >> 10516393

Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone.

C T D'Angio1, W M Maniscalco, R M Ryan, N E Avissar, K Basavegowda, R A Sinkin.   

Abstract

Corticosteroids are used to ameliorate bronchopulmonary dysplasia (BPD). They also affect normal development, including the expression of growth factors such as vascular endothelial growth factor (VEGF). Deep pulmonary lavage specimens were collected on days 1, 3, 7 and 28 of life in 40 infants of <34 weeks of gestation at birth during a randomized controlled trial of two doses of dexamethasone (DEX) at 12 and 24 h of age for BPD prophylaxis. VEGF was measured by enzyme-linked immunosorbent assay. The 18 DEX and 21 control subjects had similar gestations, birth weights and oxygen requirements at study entry. Lavage VEGF tripled between day 1 and 3 in both groups. The day 7 levels were higher in DEX subjects than in controls. DEX and control values were similar on day 28. Higher lavage VEGF levels on days 1 and 3 were also correlated with lower gestational age at birth. Lavage VEGF levels were not associated with the development of BPD. We speculate that these DEX- and age-associated changes in VEGF may affect pulmonary angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516393     DOI: 10.1159/000014168

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  11 in total

1.  Chorioamnionitis stimulates angiogenesis in saccular stage fetal lungs via CC chemokines.

Authors:  J Davin Miller; John T Benjamin; David R Kelly; David B Frank; Lawrence S Prince
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-02-19       Impact factor: 5.464

Review 2.  VEGF levels in humans and animal models with RDS and BPD: temporal relationships.

Authors:  Stephanie Meller; Vineet Bhandari
Journal:  Exp Lung Res       Date:  2012-03-06       Impact factor: 2.459

3.  Growth of pulmonary microvasculature in ventilated preterm infants.

Authors:  Monique E De Paepe; Quanfu Mao; Jessica Powell; Sam E Rubin; Philip DeKoninck; Naomi Appel; Meredith Dixon; Füsun Gundogan
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

Review 4.  Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Susanne Hay; Brett J Manley; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2021-11-11

Review 5.  Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Susanne Hay; Brett J Manley; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2021-10-21

6.  Endoglin (CD105) up-regulation in pulmonary microvasculature of ventilated preterm infants.

Authors:  Monique E De Paepe; Chintan Patel; Amy Tsai; Sravanthi Gundavarapu; Quanfu Mao
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

7.  Hyperoxia enhances VEGF release from A549 cells via post-transcriptional processes.

Authors:  Jeffrey S Shenberger; Lianqin Zhang; Richard J Powell; Aaron Barchowsky
Journal:  Free Radic Biol Med       Date:  2007-06-06       Impact factor: 7.376

Review 8.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24

9.  Combined application of 17beta-estradiol and progesterone enhance vascular endothelial growth factor and surfactant protein expression in cultured embryonic lung cells of mice.

Authors:  Andreas Trotter; Markus Kipp; Roland Matthias Schrader; Cordian Beyer
Journal:  Int J Pediatr       Date:  2009-03-01

Review 10.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.